Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00707980
Registration number
NCT00707980
Ethics application status
Date submitted
27/06/2008
Date registered
2/07/2008
Date last updated
13/12/2013
Titles & IDs
Public title
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Query!
Scientific title
A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder
Query!
Secondary ID [1]
0
0
2008-001581-91
Query!
Secondary ID [2]
0
0
LuAA21004_301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Vortioxetine
Experimental: Vortioxetine - Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
Treatment: Drugs: Vortioxetine
Encapsulated vortioxetine immediate-release tablets
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Physical Examination Findings
Query!
Assessment method [1]
0
0
Physical examination consisted of the following body systems: (1) appearance; (2) extremities; (3) skin; (4) head and neck; (5) eyes, ears, nose, and throat; (6) lungs and chest; (7) heart and cardiovascular system; (8) abdomen; and (9) musculoskeletal system. An assessment of the nervous system was conducted; any findings were captured under the appropriate body area.
Each system was assessed as normal or abnormal.
Query!
Timepoint [1]
0
0
Baseline and Week 52
Query!
Primary outcome [2]
0
0
Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
Query!
Assessment method [2]
0
0
Participants with at least one post-baseline potentially clinically significant (as defined in the table below) serum chemistry, hematology or urinalysis result. ULN = upper limit of normal; LLN = Lower limit of normal.
Query!
Timepoint [2]
0
0
Weeks 4, 8, 12, 20, 28, 36, 44 and 52
Query!
Primary outcome [3]
0
0
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
Query!
Assessment method [3]
0
0
A standard 12-lead ECG was performed at the designated study visits. The central reader reviewed and recorded the intervals (PR, QRS, RR, QT, and corrected QT interval [QTc]), and interpreted the ECG using 1 of the following categories: within normal limits or abnormal. The number of participants with at least one post-baseline potentially clinically significant ECG finding is reported. bpm = beats per minute; QTcB = QT interval corrected using Bazett's formula; QTcF = QT interval corrected using Fridericia's formula.
Query!
Timepoint [3]
0
0
Weeks 4, 12, 24, 36 and 52
Query!
Primary outcome [4]
0
0
Number of Participants With Adverse Events (AEs)
Query!
Assessment method [4]
0
0
The intensity (severity) of each AE was defined as:
Mild: caused minimal discomfort and did not interfere in a significant manner with normal activities.
Moderate: sufficiently uncomfortable to produce some impairment of normal activities.
Severe: incapacitating, preventing the patient from participating in normal activities.
The causal relationship between an AE and study drug was assessed by the investigator as Probable, Possible or Not Related; Related=AEs with causality of Possibly or Probably. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect, or was an important medical event that either jeopardized the patient, required intervention to prevent any of the SAEs defined above, a suicide attempt or an abortion.
Query!
Timepoint [4]
0
0
From the first dose of open-label study drug until 4 weeks after the last dose (up to 56 weeks)
Query!
Primary outcome [5]
0
0
Number of Participants With Potentially Clinically Significant Vital Sign Findings
Query!
Assessment method [5]
0
0
Participants with at least one potentially clinically significant post-baseline vital sign finding. The definition of clinically significant is included in the table below for each parameter. SSBP = supine systolic blood pressure; SDBP = supine diastolic blood pressure.
Query!
Timepoint [5]
0
0
Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52
Query!
Secondary outcome [1]
0
0
Change From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score
Query!
Assessment method [1]
0
0
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Query!
Timepoint [1]
0
0
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52.
Query!
Secondary outcome [2]
0
0
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
Query!
Assessment method [2]
0
0
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Query!
Timepoint [2]
0
0
Baseline and Weeks 4, 24 and 52
Query!
Secondary outcome [3]
0
0
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
Query!
Assessment method [3]
0
0
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Query!
Timepoint [3]
0
0
Baseline and Weeks 4, 24 and 52
Query!
Secondary outcome [4]
0
0
Change From Baseline in the Clinical Global Impression of Severity of Illness Scale
Query!
Assessment method [4]
0
0
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Query!
Timepoint [4]
0
0
Baseline and Weeks 4, 24 and 52
Query!
Secondary outcome [5]
0
0
Change From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36)
Query!
Assessment method [5]
0
0
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst).
Query!
Timepoint [5]
0
0
Baseline and Week 52
Query!
Secondary outcome [6]
0
0
Change From Baseline to the Final Visit in the Sheehan Disability Scale
Query!
Assessment method [6]
0
0
The Sheehan Disability Scale (SDS) assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
Query!
Timepoint [6]
0
0
Baseline and Week 52
Query!
Secondary outcome [7]
0
0
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
Query!
Assessment method [7]
0
0
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
Query!
Timepoint [7]
0
0
Baseline and Week 52
Query!
Eligibility
Key inclusion criteria
- Has completed the double blind treatment period of either study Lu AA21004_304
(NCT00672620) or LuAA21004_305 (NCT00735709) immediately prior to enrollment in the
extension study (ie, the baseline visit is the same visit as the completion visit of
the double blind treatment of the preceding protocol).
- Suffers from a major depressive episode as the primary diagnosis according to
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR) criteria (classification code 296.xx) at entry into the prior Lu
AA21004_304 or Lu AA21004_305 study.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
76
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- In addition to meeting the exclusion criteria for studies Lu AA21004_304 or Lu
AA21004_305 at the time of enrollment into those studies respectively, with the
exception of the criteria prohibiting previous exposure to Lu AA21004 and
investigational drugs, and the criteria prohibiting patients with increased
intraocular pressure, or risk of acute narrow-angle glaucoma, the following exclusion
criteria apply:
- Has Major Depressive Disorder for whom other psychiatric disorders (mania,
bipolar disorder, schizophrenia, or any psychotic disorder) have been diagnosed
during the prior study.
- The participant, in the investigator's opinion, has a significant risk of suicide
and/or a score of =5 points on item 10 (suicidal thoughts) of the Montgomery
Åsberg Depression Rating Scale.
- The participant, in the opinion of the investigator, is unlikely to comply with
the clinical study protocol or is unsuitable for any reason.
- Has a clinically significant moderate or severe ongoing adverse event related to
study medication from the prior study.
- Has used/uses disallowed concomitant medication.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
836
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Elizabeth Vale
Query!
Recruitment hospital [2]
0
0
- Richmond
Query!
Recruitment hospital [3]
0
0
- Southport
Query!
Recruitment postcode(s) [1]
0
0
- Elizabeth Vale
Query!
Recruitment postcode(s) [2]
0
0
- Richmond
Query!
Recruitment postcode(s) [3]
0
0
- Southport
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kentucky
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Mississippi
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oklahoma
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Utah
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Wisconsin
Query!
Country [19]
0
0
Croatia
Query!
State/province [19]
0
0
Osijek
Query!
Country [20]
0
0
Croatia
Query!
State/province [20]
0
0
Zagreb
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Bully les Mines
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Marseille
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Strasbourg
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Berlin
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Bochum
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Chemnitz
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Huettenberg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Leipzig
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
München
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Nuernberg
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Wiesbaden
Query!
Country [32]
0
0
Korea, Republic of
Query!
State/province [32]
0
0
Buchon
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Gyeonggi-do
Query!
Country [34]
0
0
Korea, Republic of
Query!
State/province [34]
0
0
Incheon
Query!
Country [35]
0
0
Korea, Republic of
Query!
State/province [35]
0
0
Seoul
Query!
Country [36]
0
0
Latvia
Query!
State/province [36]
0
0
Liepaja
Query!
Country [37]
0
0
Latvia
Query!
State/province [37]
0
0
Riga
Query!
Country [38]
0
0
Latvia
Query!
State/province [38]
0
0
Sigulda
Query!
Country [39]
0
0
Lithuania
Query!
State/province [39]
0
0
Siauliai
Query!
Country [40]
0
0
Lithuania
Query!
State/province [40]
0
0
Vilnius
Query!
Country [41]
0
0
Malaysia
Query!
State/province [41]
0
0
Kuala Lumpur
Query!
Country [42]
0
0
Netherlands
Query!
State/province [42]
0
0
SchHoogfliet
Query!
Country [43]
0
0
Netherlands
Query!
State/province [43]
0
0
Wildervank
Query!
Country [44]
0
0
Netherlands
Query!
State/province [44]
0
0
Zwijndrecht
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Bialystok
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Leszno
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Pruszków
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Skórzewo
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Torun
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Tuszyn
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
Moscow
Query!
Country [52]
0
0
Russian Federation
Query!
State/province [52]
0
0
Nizhny Novgorod
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Novosibirsk
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Omsk
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
St. Petersburg
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Stavropol
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Tomsk
Query!
Country [58]
0
0
Serbia
Query!
State/province [58]
0
0
Belgrade
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
Bryanston
Query!
Country [60]
0
0
South Africa
Query!
State/province [60]
0
0
Durban
Query!
Country [61]
0
0
South Africa
Query!
State/province [61]
0
0
Lyttelton
Query!
Country [62]
0
0
South Africa
Query!
State/province [62]
0
0
NoordHeuwel
Query!
Country [63]
0
0
South Africa
Query!
State/province [63]
0
0
Pretoria
Query!
Country [64]
0
0
Taiwan
Query!
State/province [64]
0
0
Kaohsiung
Query!
Country [65]
0
0
Ukraine
Query!
State/province [65]
0
0
Dnepropetrovsk
Query!
Country [66]
0
0
Ukraine
Query!
State/province [66]
0
0
Kiev
Query!
Country [67]
0
0
Ukraine
Query!
State/province [67]
0
0
Lugansk
Query!
Country [68]
0
0
Ukraine
Query!
State/province [68]
0
0
Simferopol
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
Glasgow
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Takeda
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
H. Lundbeck A/S
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine,
once daily (QD), in adults with major depressive disorder.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00707980
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director, Clinical Science
Query!
Address
0
0
Takeda
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00707980
Download to PDF